


1 **Budesonide**

2 ブデソニド

4  $C_{25}H_{34}O_6$ : 430.535 16 $\alpha$ ,17-[(1*R*S)-Butyridenebis(oxy)]-11 $\beta$ ,21-dihydroxypregna-1,4-

6 diene-3,20-dione

7 [51333-22-3]

8

9 Budesonide is a mixture of epimers at the asym-

10 metric carbon C-22.

11 Budesonide contains not less than 98.0% and not  
12 more than 102.0% of budesonide ( $C_{25}H_{34}O_6$ ), calcu-  
13 lated on the dried basis.14 **Description** Budesonide occurs as white to pale yel-  
15 low-white, crystals or crystalline powder.16 It is soluble in methanol, sparingly soluble in acetonitrile  
17 and in ethanol (99.5), and practically insoluble in water.18 Optical rotation:  $[\alpha]_D^{25}$ : +102 – +109° (0.25 g, methanol,  
19 25 mL, 100 mm).

20 Melting point: about 240°C (with decomposition).

21 **Identification** (1) Determine the absorption spectrum of  
22 a solution of Budesonide (1 in 40,000) as directed under  
23 Ultraviolet-visible Spectrophotometry <2.24>, and compare  
24 the spectrum with the Reference Spectrum or the spectrum  
25 of a solution of Budesonide RS prepared in the same man-  
26 ner as the sample solution: both spectra exhibit similar in-  
27 tensities of absorption at the same wavelengths.28 (2) Determine the infrared absorption spectrum of  
29 Budesonide as directed in the potassium bromide disk  
30 method under Infrared Spectrophotometry <2.25>, and  
31 compare the spectrum with the Reference Spectrum or the  
32 spectrum of Budesonide RS: both spectra exhibit similar  
33 intensities of absorption at the same wave numbers.34 **Purity** (1) Heavy metals—Being specified separately  
35 when the drug is granted approval based on the Law.36 (2) Related substances—Conduct this procedure with-  
37 out exposure to light, using light-resistant vessels. Dissolve  
38 50 mg of Budesonide in 15 mL of acetonitrile, add phos-  
39 phate buffer solution (pH 3.2) to make 50 mL, and use this  
40 solution as the sample solution. Perform the test with 20  $\mu$ L  
41 of the sample solution as directed under Liquid Chromatog-  
42 raphy <2.01> according to the following conditions. Deter-  
43 mine each peak area by the automatic integration method,  
44 and calculate the amount of them by the area percentage45 method: the amounts of the peaks of related substances A  
46 and L, having the relative retention times of about 0.1 and  
47 about 0.95 to the first eluted peak (epimer B) of the two  
48 peaks of budesonide, are not more than 0.2%, respectively,  
49 the sum of the amounts of the peaks of related substance D,  
50 having the relative retention times of about 0.63 and about  
51 0.67, and the sum of the amounts of the peaks of the related  
52 substance K, having the relative retention times of about 2.9  
53 and about 3.0, are not more than 0.2%, respectively, and the  
54 amount of the peak other than budesonide and mentioned  
55 above is not more than 0.1%. Furthermore, the total amount  
56 of the peaks other than budesonide is not more than 0.5%.  
57 For the peak areas of the related substances D and K, multi-  
58 ply their relative response factors, 1.8 and 1.3, respectively.59 *Operating conditions*—60 Detector, column, column temperature and flow rate:  
61 Proceed as directed in the operating conditions in the Assay.62 Mobile phase A: A mixture of phosphate buffer solution  
63 (pH 3.2), acetonitrile for liquid chromatography and ethanol  
64 (99.5) (34:16:1).65 Mobile phase B: A mixture of phosphate buffer solution  
66 (pH 3.2) and acetonitrile for liquid chromatography (1:1).67 Flowing of mobile phase: Control the gradient by mixing  
68 the mobile phases A and B as directed in the following ta-  
69 ble.

Time after injection of sample (min)	Mobile phase A (vol%)	Mobile phase B (vol%)
0 – 38	100	0
38 – 50	100 → 0	0 → 100
50 – 60	0	100

71

72 Time span of measurement: For 60 minutes after injec-  
73 tion, beginning after the solvent peak.74 *System suitability*—75 Test for required detectability: Pipet 1 mL of the sample  
76 solution add a mixture of phosphate buffer solution (pH 3.2)  
77 and acetonitrile (17:8) to make exactly 10 mL. Pipet 1 mL  
78 of this solution, add a mixture of phosphate buffer solution  
79 (pH 3.2) and acetonitrile (17:8) to make exactly 100 mL,  
80 and use this solution as the solution for system suitability  
81 test. When the procedure is run with 20  $\mu$ L of the solution  
82 for system suitability test under the above operating condi-  
83 tions, the SN ratio of the second eluted peak (epimer A) of  
84 the two peaks of budesonide is not less than 10.85 System performance: When the procedure is run with 20  
86  $\mu$ L of the solution for system suitability test under the above  
87 operating conditions, the resolution between the two peaks  
88 of budesonide is not less than 1.5.89 **Loss on drying** <2.41> Not more than 0.5% (1 g, 105°C, 3  
90 hours).

91 **Isomer ratio** Conduct this procedure without exposure to  
 92 light, using light-resistant vessels. Perform the test with 20  
 93  $\mu\text{L}$  of the sample solution obtained in the Assay as directed  
 94 under Liquid Chromatography <2.01> according to the fol-  
 95 lowing conditions. Determine the peak areas,  $A_b$  and  $A_a$ ,  
 96 where  $A_b$  is the area of the early eluted peak and  $A_a$  is the  
 97 area of the lately eluted peak of the two peaks of  
 98 budesonide:  $A_a/(A_a+A_b)$  is between 0.40 and 0.51.

99 *Operating conditions*—

100 Proceed as directed in the operating conditions in the As-  
 101 say.

102 *System suitability*—

103 **System performance:** Proceed as directed in the system  
 104 suitability in the Assay.

105 **Assay** Conduct this procedure without exposure to light,  
 106 using light-resistant vessels. Weigh accurately about 25 mg  
 107 each of Budesonide and Budesonide RS (separately deter-  
 108 mine the loss on drying <2.41> under the same conditions as  
 109 Budesonide), dissolve each in 15 mL of acetonitrile, add  
 110 phosphate buffer solution (pH 3.2) to make exactly 50 mL,  
 111 and use these solutions as the sample solution and the  
 112 standard solution, respectively. Perform the test with exact-  
 113 ly 20  $\mu\text{L}$  each of the sample solution and standard solution  
 114 as directed under Liquid Chromatography <2.01> according  
 115 to the following conditions, and determine the peak areas,  
 116  $A_T$  and  $A_S$ , of the sum of the two peak areas of budesonide  
 117 in each solution.

118 Amount (mg) of budesonide ( $\text{C}_{25}\text{H}_{34}\text{O}_6$ ) =  $M_S \times A_T/A_S$

119  $M_S$ : Amount (mg) of Budesonide RS taken, calculated on  
 120 the dried basis

121 *Operating conditions*—

122 **Detector:** An ultraviolet absorption photometer (wave-  
 123 length: 240 nm).

124 **Column:** A stainless steel column 4.6 mm in inside diam-  
 125 eter and 15 cm in length, packed with octadecylsilanized  
 126 silica gel for liquid chromatography (3  $\mu\text{m}$  in particle diam-  
 127 eter).

128 **Column temperature:** A constant temperature of about  
 129 50°C.

130 **Mobile phase:** A mixture of phosphate buffer solution  
 131 (pH 3.2), acetonitrile for liquid chromatography and ethanol  
 132 (99.5) (34:16:1).

133 **Flow rate:** 1.0 mL per minute (the retention times of two  
 134 peaks of budesonide are about 17 and about 19 minutes).

135 *System suitability*—

136 **System performance:** When the procedure is run with 20  
 137  $\mu\text{L}$  of the standard solution under the above operating con-  
 138 ditions, the resolution between the two peaks of budesonide  
 139 is not less than 1.5.

140 **System repeatability:** When the test is repeated 6 times  
 141 with 20  $\mu\text{L}$  of the standard solution under the above operat-  
 142 ing conditions, the relative standard deviation of the sum of  
 143 the two peak areas of budesonide is not more than 1.0%.


144 **Containers and storage** Containers—Tight containers.

145 Storage—Light-resistant.

146 **Others**

147 Related substance A:

148 11 $\beta$ ,16 $\alpha$ ,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione




149

150

151 Related substance D:

152 16 $\alpha$ ,17-[(1*RS*)-Butylidenebis(oxy)]-11 $\beta$ -hydroxy-3,20-  
 153 dioxopregna-1,4-dien-21-al




154

and epimer at C\*

155

156 Related substance K:

157 16 $\alpha$ ,17-[(1*RS*)-Butylidenebis(oxy)]-11 $\beta$ ,21-  
 158 dihydroxypregna-1,4-diene-3,20-dione 21-acetate




159

and epimer at C\*

160

161 Related substance L:

162 16 $\alpha$ ,17-[(1*RS*)-Butylidenebis(oxy)]-21-hydroxypregna-1,4-  
 163 diene-3,11,20-trione



164

and epimer at C\*

165 *Add the following to 9.01 Reference*

166 *Standards (1):*

167 **Budesonide RS**

168 *Add the following to 9.41 Reagents, Test*

169 *Solutions:*

170 **Phosphate buffer solution (pH 3.2)** To 900 mL of a  
171 solution of sodium dihydrogenphosphate dihydrate (1 in  
172 250) add 100 mL of a solution of phosphoric acid (1 in 400),  
173 and adjust to pH 3.2 with phosphoric acid or sodium hy-  
174 droxide TS.